McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin E. Noonan is quoted in an October 3, 2017 edition of the BioPharma-Reporter in an article entitled, “Six year wait for Humira biosimilar a win-win for Amgen and AbbVie, aays lawyer.” Amjevita (adalimumab-atto) became the first biosimilar version of AbbVie’s best-selling monoclonal antibody Humira to be approved in the US last September. European approval came in January under the name Amgevita. view the article